Publications by authors named "Giulia Pesch"

Claim this Profile
D
Deep Immune Phenotyping Reveals Distinct Immunopathogenesis in Checkpoint Inhibitor-Induced Colitis Compared with Ulcerative Colitis.
Giulia Pesch, Ignazio Piseddu, Jan Gaertig, Nora Kramer, Rafaela Kramer

Cancer Immunol Res· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to "Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients' health-related quality of life" [Eur J Cancer 176 (2022) 88-99].
Thomas U Schulz, Sarah Zierold, Michael M Sachse, Giulia Pesch, Dirk Tomsitz

Eur J Cancer· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stringent monitoring can decrease mortality of immune checkpoint inhibitor induced cardiotoxicity.
Ying Wang, Carolin Ertl, Christina Schmitt, Linda Hammann, Rafaela Kramer, Giulia Pesch

Front Cardiovasc Med· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related quality of life (EuroQol 5D-5L) in patients with autoimmunity in the context of immunotherapy: A large dataset comprising cancer patients after cessation of checkpoint inhibitor therapy and patients with autoimmune diseases.
Thomas U Schulz, Sarah Zierold, Michael M Sachse, Giulia Pesch, Dirk Tomsitz

Data Brief· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients' health-related quality of life.
Thomas U Schulz, Sarah Zierold, Michael M Sachse, Giulia Pesch, Dirk Tomsitz

Eur J Cancer· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of Lymphopenia during Therapy with Immune Checkpoint Inhibitors Is Associated with Poor Outcome in Metastatic Cutaneous Melanoma.
Dirk Tomsitz, Max Schlaak, Sarah Zierold, Giulia Pesch, Thomas U Schulz

Cancers (Basel)· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis